Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

Literature DB >> 29413471

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC.

Etienne Garin¹, Yan Rolland², Boris Campillo-Gimenez³, Julien Edeline⁴.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2018 PMID： 29413471 DOI： 10.1016/S1470-2045(18)30024-X

Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316

Keyword Cloud
Cited

× No keyword cloud information.

4 in total

1. Comparative dosimetry between ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT in primary and metastatic liver tumors.

Authors: Alexandre Jadoul; Claire Bernard; Pierre Lovinfosse; Laurent Gérard; Henri Lilet; Olivier Cornet; Roland Hustinx
Journal: Eur J Nucl Med Mol Imaging Date: 2019-08-06 Impact factor: 9.236

2. Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres.

Authors: S C Ebbers; B Kunnen; B J van Nierop; J L M Bemelmans; G C Krijger; M G E H Lam; A J A T Braat
Journal: Cardiovasc Intervent Radiol Date: 2020-05-20 Impact factor: 2.740

Review 3. Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design.

Authors: Etienne Garin; Xavier Palard; Yan Rolland
Journal: Cancers (Basel) Date: 2020-06-12 Impact factor: 6.639

4. Inter-observer variability of ⁹⁰Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization.

Authors: Nicolas Meyers; Alexandre Jadoul; Claire Bernard; Jean Delwaide; Anne Lamproye; Olivier Detry; Pierre Honoré; Laurent Gerard; Roland Hustinx
Journal: EJNMMI Phys Date: 2020-05-12

4 in total

Negative phase 3 study of 90Y microspheres versus sorafenib in HCC.

1. Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors.

2. Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres.

Review 3. Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design.

4. Inter-observer variability of 90Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization.

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC.

1. Comparative dosimetry between ^99mTc-MAA SPECT/CT and ⁹⁰Y PET/CT in primary and metastatic liver tumors.

4. Inter-observer variability of ⁹⁰Y PET/CT dosimetry in hepatocellular carcinoma after glass microspheres transarterial radioembolization.